Scinnohub Pharmaceutical Co. Ltd. has identified S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors reported to be useful for the treatment of cancer.
Shanghai Ringene Biopharma Co. Ltd. has synthesized CDK7/cyclin H inhibitors reported to be useful for the treatment of cancer, hemolytic anemia, rheumatoid arthritis, psoriasis, systemic lupus erythematosus, sepsis, idiopathic thrombocytopenic purpura and ulcerative colitis, among others.
JS Innomed Holdings Ltd. has disclosed heterocyclic compounds acting as tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) inhibitors reported to be useful for the treatment of cancer, LEOPARD syndrome and Noonan syndrome.
The U.S. Court of Appeals for the Federal Circuit has once again ruled on a patent dispute between Masimo Corp., of Irvine, Calif., and a rival firm, this time with Sotera Wireless Inc., of San Diego serving as the adversary. The Federal Circuit sided with Sotera in decreeing that 17 claims in Masimo’s RE47,218 (the ’218 patent) are invalidated due to the existence of prior art that rendered the claims obvious, but the irony in this litigation is that one of the patents cited by Sotera as prior art, the 6,597,933 patent, was authored in part by Joe Kiani, the founder, CEO and board chairman of Masimo.
Connex Biomedical Inc. applied for patent protection for a transcardiac access port affixed and retained post-procedure on the cardiac muscle, such as the ventricular myocardium, and an access port delivery system configured to deliver the access port, secure the access port to the muscle tissue with tissue anchors, and provide a working channel through the access port to facilitate transcardiac access and device delivery.
Merck Sharp & Dohme Ltd. has described ceramide glucosyltransferase (glucosylceramide synthase; GLCT-1) inhibitors reported to be useful for the treatment of cancer, Lewy body dementia, diabetes, obesity, polycystic kidney disease, neurodegeneration, lysosomal storage disease and Parkinson’s disease, among others.
Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co Ltd. have identified heterocyclic derivatives acting as Ras-related C3 botulinum toxin substrate 1 (RAC1; TC25) inhibitors reported to be useful for the treatment of melanoma, Menkes disease, rheumatoid arthritis, atherosclerosis, type 1 diabetes, Huntington’s disease and Alzheimer’s disease.
Astellas Pharma Inc. has divulged proteolysis targeting chimera (PROTAC) compounds acting as GTPase KRAS (G12D mutant) degradation inducers reported to be useful for the treatment of pancreatic cancer.
Researchers from Ascentage Pharma Group International and Ascentage Pharma (Suzhou) Co. Ltd. have synthesized tricyclic compounds acting as inhibitor of apoptosis proteins (IAP) inhibitors reported to be useful for the treatment of cancer, AIDS, autoimmune disease, immune thrombocytopenia (idiopathic thrombocytopenic purpura), infections, psoriasis, rheumatoid arthritis, and inflammatory disorders, among others.
Scorpion Therapeutics Inc. has disclosed tetrahydroindole derivatives acting as EGFR (HER1; erbB1) and/or HER2 (erbB2) inhibitors reported to be useful for the treatment of cancer.
RSS
